Vaccine research lab and office facility
China’s largest animal vaccine company Jinyu Bio-technology unveiled plans to establish its first US-based vaccine research lab and office facility in May 2017.
The new facility will be situated within the Kansas State University Office Park phase II building, which is located on north side of the Kansas State University in the city of Manhattan, Kansas.
The ceremonial ground-breaking for the project was held in June 2017.
Jinyu’s new laboratory is scheduled to become operational in August 2018 and will employ between four and six scientific researchers, who will focus primarily on animal health research.
Jinyu USA will also collaborate with the State of Kansas, the City of Manhattan and Kansas State University to develop and produce new animal health products for the Chinese, Asian, African and American markets.
Jinyu’s vaccine research lab and office facility will house three offices, a 2,400ft² research lab 800ft² and clean room space.
The site will feature state-of-the-art equipment to conduct research and design of vaccines to treat and control parasites in swine and cattle.
The facility will also focus on the development of educational materials to assist Chinese companies and veterinarians.
The new facility is part of the 60,000ft² phase II expansion of the Kansas State University Office Park, located in the Kansas City Animal Health Corridor.
It is being developed by the fundraising arm of Kansas State University, KSU Foundation.
The site will be situated close to approximately 300 animal health companies, the Kansas State University College of Veterinary Medicine, the National Bio and Agro Defense Facility, Biosecurity Research Institute, and several cutting-edge research facilities.
The company intends to deploy its future manufacturing facilities in the Corridor.
Jinyu held discussions with the officials of the state of Kansas, the city of Manhattan, and other organisations for two years for the construction of the research lab and office in the Kansas State University Office Park building.
Jinyu’s new vaccine research site will allow the company to build long-term, mutually beneficial relationships with partners in Kansas.
It will also help the company to develop technical innovation and expertise in animal health research.
Additionally, the incorporation of Jinyu’s new laboratory into the Kansas State University Office Park phase II building is expected to support Kansas State University’s research and development activities in the biopharmaceutical sector.
The facility will also contribute to the economic growth in Pottawatomie, Riley and Geary counties by creating employment opportunities and partnerships.
Jinyu Bio-technology was founded in March 1993 and has an employee base of approximately 1,100. It is currently headquartered in Hohhot, the capital city of Inner Mongolia.
The company is engaged in the development, manufacturing and sale of foot and mouth disease (FMD) vaccines and veterinary biological products to Chinese and international markets, including Mongolia, Bangladesh and Egypt.
Jinyu was responsible for the construction of China’s only Veterinary Vaccine National Engineering Lab in 2008, which covers 10,900m² and conducts scientific research and experiments relating to animal health, and the production of veterinary vaccines.
The company is currently building Jinyu International Biotechnology Industrial Park in Hohhot, China, to research and develop advanced animal vaccines. The park is expected to be opened in 2018.
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…